Abstract
The metabolic shift that cancer cells undergo towards aerobic glycolysis was identified as a defining feature in tumours almost 100 years ago; however, it has only recently become apparent that similar metabolic reprogramming is a key feature in other diseases - with fibrosis now entering the fray. In this perspective, an overview of the recent evidence implicating increased glycolysis and glutaminolysis as mediators of fibrosis is presented, with a particular emphasis on the novel therapeutic possibilities this introduces. Furthermore, the impact that metabolic reprogramming has on redox homeostasis is discussed, providing an insight into how this often-overlooked mechanism may drive the pathogenesis. [Abstract copyright: Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.]
Original language | English |
---|---|
Pages (from-to) | 639-653 |
Number of pages | 15 |
Journal | Trends in Endocrinology and Metabolism |
Volume | 32 |
Issue number | 8 |
Early online date | 20 May 2021 |
DOIs | |
Publication status | Published - 1 Aug 2021 |